Matthew W. Foehr - 15 Feb 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
President and COO
Signature
By: Charles S. Berkman For: Matthew W. Foehr
Issuer symbol
LGND
Transactions as of
15 Feb 2022
Net transactions value
-$438,569
Form type
4
Filing time
16 Feb 2022, 19:24:09 UTC
Previous filing
28 Jan 2022
Next filing
03 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Tax liability $152,621 -1,234 -0.71% $123.68 173,166 15 Feb 2022 Direct F1
transaction LGND Common Stock Tax liability $151,137 -1,222 -0.71% $123.68 171,944 15 Feb 2022 Direct F2
transaction LGND Common Stock Tax liability $134,811 -1,090 -0.63% $123.68 170,854 15 Feb 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019.
F2 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020.
F3 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/03/2021.